Two-drug combination boosts survival in patients with metastatic, hormone-sensitive prostate cancer

Patients with newly diagnosed metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit with simultaneous initiation of two drugs, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical trial recently published in The New England Journal of Medicine (2015; doi:10.1056/NEJMoa1503747). Patients who underwent six cycles of more »

An Excellent Review of Current Imaging and Positron Emission Tomography (PET) Scanning and Their Use in Managing Recurrent and Advanced Disease

This website initially posted a review of positron emission tomography (PET) scanning on March 9th, 2015. More recently, the Prostate Cancer Research Institute (PCRI) November Insights contained an updated and very informative review of the latest PET imaging techniques for managing recurrent and advanced prostate cancer. Their major utilities, advantages and their limitations are discussed more »

Two New DNA Cancer Vaccines in Phase 1 and Phase 2 Clinical Trials

Madison Vaccines Incorporated (MVI, see the linked news release), has begun a Phase 1 clinical trial for MVI-118 (pTVG-AR) in men with metastatic prostate cancer who are initiating androgen deprivation (hormonal) therapy (ADT). MVI-118 targets the human androgen receptor, the critical biological target responsible for driving prostate cancer progression and, in many cases, resistance to more »

Hormonal (Testosterone Lowering) Therapy (ADT) Linked to Increased Dementia Risk for Prostate Cancer Patients.

It isn’t often that a research finding appears in 4-5 e mail or other  publications but such is the case herein.  Researchers at Stanford University School of Medicine published a study entitled “Association Between Androgen Deprivation Therapy and the Risk of Dementia” in the journal Journal of the American Medical Association Oncology. They reported that men more »

Monitoring, Not Treatment, May be Better for Very Low-Risk Prostate Cancer Patients

In a study published online on Oct. 20th in the Journal of the American Medical Association (JAMA) Oncology, more than 90 percent of men in Sweden who have very low-risk prostate cancer choose close monitoring rather than immediate treatment — and more American men should use that option, researchers say. In a study of nearly more »

Radiation Therapy Improves Survival Over Hormone Therapy (ADT) Alone in Metastatic Prostate Cancer

A large database analysis showed that the addition of external beam radiotherapy (RT) to androgen deprivation therapy (ADT) significantly improves overall survival (OS) in men with metastatic prostate cancer. “As advances in systemic therapy for metastatic prostate cancer have improved OS and the control of metastatic disease, a greater interest has emerged in therapies to more »

Men with Advanced Prostate Cancer Should Consider Genetic Testing

In the light of recent discoveries (recently posted on this website) that some advanced prostate cancer patients harbor specific genetic mutations, a recent study summarized in the July 7th National Library of Medicine MedLine Plus suggested that testing for inherited abnormalities in DNA repair genes could provide patients and family members important information about their more »


Three weeks ago, a good friend called me from his vacation to say his PSA had jumped from 4-5 to 8-9 within a few months. My friend was a Christian who definitely had a personal relationship with God through Jesus Christ. But he was very anxious as we probably all would be or have been more »

High Prostate Cancer Risk Linked to Inherited Mutations in DNA-Repair Genes.

Mutations in DNA-repair genes, including the breast cancer genes BRCA1 and BRCA2, are involved in an inherited high risk of prostate cancer and, potentially, the risk of an aggressive cancer, according to researchers at Fred Hutchinson Cancer Research Center and the University of Washington. The study entitled, “Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer”,  published in The more »

Custersin Fails to Improve Survival in Advanced Prostate Cancer Patients

The Phase 3 AFFINITY Trial failed to met its primary endpoint of significantly improved overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) being treated with custirsen, the therapy’s maker, OncoGenex announced. The international, randomized, open-label study evaluated 634 men with CRPC whose disease had progressed despite treatment with docetaxel (taxotere). In the trial, patients more »

Potential Diagnosis of Prostate Cancer Using Urine Biomarker Protein Signatures.

A recent study revealed protein biomarker combinations in urine that are unique to prostate cancer and 2 of its stages.  A team from the University Health Network in Toronto Canada analyzed urine samples from 50 patients with prostate cancer — 37 with prostate-confined tumors and 13 with tumors that spread — and 24 healthy controls. A targeted protein screen more »